However, due to the dynamic interplay between these antibodies and the immune microenvironment, as well as the variability in the immune milieu across different tumor types, the available evidence surrounding the predictiveness of PD-L1 expression is fraught with contradiction and ambiguity [24,25,26,27]. The gene discussed is CD274; the disease is neoplasm.